D-Cycloserine supported exposure in panic disorder

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-004860-29-DE

Enrollment

Registered

2006-12-07

Start date

2007-05-11

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Panic disorder agoraphobia

Interventions

Trade Name: Seromycin Product Name: D-Cycloserine Pharmaceutical Form: Capsule, hard INN or Proposed INN: D-CYCLOSERINE CAS Number: 68417 Concentration unit: mg milligram(s) Concentration type: equal

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Panic disorder and or Agoraphobia Written informed consent Age: 18-70 Jahre Negative pregnancy test and contraception in female subjets Compliance of the patient Adequate communication skills Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Other mental disorders like schizophrenia, substance related disorder, Ddmentia Acute suicidality Pregnancy and breast feedin Psychotropic drugs must be stopped at least 3 half lives before Severe medical disorders, Prior changes in sleep wake cycle Starting a cognitive behavioral therapy within the last 3 months

Design outcomes

Primary

Measure	Time frame
Main Objective: To show that the additional administration of 50 mg D-Cycloserine increases the clinical effectiveness of exposure therapy in panic diosrder patients as measured with the Panic and Agoraphobia Scale;Secondary Objective: To show that the additional administration of 50 mg D-Cycloserine increases the clinical effectiveness of exposure therapy in panic diosrder patients as measured with the Mobility Inventory, Beck Anxiety Inventory and Hamilton Anxiety Scale.;Primary end point(s): Sum Score of the Panic and Agorphobia Scale	—

Measure

Time frame

Main Objective: To show that the additional administration of 50 mg D-Cycloserine increases the clinical effectiveness of exposure therapy in panic diosrder patients as measured with the Panic and Agoraphobia Scale;Secondary Objective: To show that the additional administration of 50 mg D-Cycloserine increases the clinical effectiveness of exposure therapy in panic diosrder patients as measured with the Mobility Inventory, Beck Anxiety Inventory and Hamilton Anxiety Scale.;Primary end point(s): Sum Score of the Panic and Agorphobia Scale

—

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026